EE459 Is Adding Ribociclib to Fulvestrant Cost-Effective in Treating Post-Menopausal Women with HR+/ HER2- Advanced Breast Cancer - a US Payer Perspective Cost-Utility Analysis Academic Article uri icon

published proceedings

  • Value in Health

author list (cited authors)

  • Berrios, K., Burum, A., Jeong, E., & Zhong, L.

citation count

  • 0

complete list of authors

  • Berrios, K||Burum, A||Jeong, E||Zhong, L

publication date

  • January 2022